4,190 reports of this reaction
2.1% of all TIRZEPATIDE reports
#11 most reported adverse reaction
CONSTIPATION is the #11 most commonly reported adverse reaction for TIRZEPATIDE, manufactured by Eli Lilly and Company. There are 4,190 FDA adverse event reports linking TIRZEPATIDE to CONSTIPATION. This represents approximately 2.1% of all 196,029 adverse event reports for this drug.
TIRZEPATIDE has an overall safety score of 78 out of 100. Patients taking TIRZEPATIDE who experience constipation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONSTIPATION is a less commonly reported adverse event for TIRZEPATIDE, but still significant enough to appear in the safety profile.
In addition to constipation, the following adverse reactions have been reported for TIRZEPATIDE:
The following drugs have also been linked to constipation in FDA adverse event reports:
CONSTIPATION has been reported as an adverse event in 4,190 FDA reports for TIRZEPATIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONSTIPATION accounts for approximately 2.1% of all adverse event reports for TIRZEPATIDE, making it a notable side effect.
If you experience constipation while taking TIRZEPATIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.